277 related articles for article (PubMed ID: 21320556)
1. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
[TBL] [Abstract][Full Text] [Related]
2. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
[TBL] [Abstract][Full Text] [Related]
3. Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.
Ueda Y; Mori K; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2011 Jun; 409(4):663-8. PubMed ID: 21620801
[TBL] [Abstract][Full Text] [Related]
4. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.
Panigrahi R; Hazari S; Chandra S; Chandra PK; Datta S; Kurt R; Cameron CE; Huang Z; Zhang H; Garry RF; Balart LA; Dash S
PLoS One; 2013; 8(8):e72791. PubMed ID: 24009705
[TBL] [Abstract][Full Text] [Related]
5. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
Sun Y; Chung DH; Chu YK; Jonsson CB; Parker WB
Antimicrob Agents Chemother; 2007 Jan; 51(1):84-8. PubMed ID: 17060520
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
[TBL] [Abstract][Full Text] [Related]
7. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
Zhou S; Liu R; Baroudy BM; Malcolm BA; Reyes GR
Virology; 2003 Jun; 310(2):333-42. PubMed ID: 12781720
[TBL] [Abstract][Full Text] [Related]
8. Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris.
Ueda Y; Mori K; Satoh S; Dansako H; Ikeda M; Kato N
Biochem Biophys Res Commun; 2014 May; 447(2):341-5. PubMed ID: 24726408
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
[TBL] [Abstract][Full Text] [Related]
10. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
Pfeiffer JK; Kirkegaard K
J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.
Matsuno K; Ueda Y; Fukuda M; Onoda K; Waki M; Ikeda M; Kato N; Miyachi H
Bioorg Med Chem Lett; 2014 Sep; 24(17):4276-80. PubMed ID: 25086684
[TBL] [Abstract][Full Text] [Related]
13. New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.
Ueda Y; Takeda M; Mori K; Dansako H; Wakita T; Kim HS; Sato A; Wataya Y; Ikeda M; Kato N
PLoS One; 2013; 8(8):e72519. PubMed ID: 24023620
[TBL] [Abstract][Full Text] [Related]
14. STAT3 induces anti-hepatitis C viral activity in liver cells.
Zhu H; Shang X; Terada N; Liu C
Biochem Biophys Res Commun; 2004 Nov; 324(2):518-28. PubMed ID: 15474458
[TBL] [Abstract][Full Text] [Related]
15. Treating HCV with ribavirin analogues and ribavirin-like molecules.
Gish RG
J Antimicrob Chemother; 2006 Jan; 57(1):8-13. PubMed ID: 16293677
[TBL] [Abstract][Full Text] [Related]
16. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
[TBL] [Abstract][Full Text] [Related]
17. Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus.
Buckwold VE
J Antimicrob Chemother; 2004 Mar; 53(3):413-4. PubMed ID: 14963071
[TBL] [Abstract][Full Text] [Related]
18. Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin.
Zhao LJ; Wang W; Liu Y; Ren H; Qi ZT
Antiviral Res; 2012 Nov; 96(2):260-8. PubMed ID: 22985631
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
[TBL] [Abstract][Full Text] [Related]
20. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
